



CURRICULUM VITAE

Personal details:

Name, Surname: **LAURA IULIA BĂRCUȚEAN**

Academic Title: **University Assistant**

Department: **Neurology, ME2**

Institutional e-mail: **laura.barcutean@umfst.ro**

Areas of interest (maximum 5 domains):

Multiple Sclerosis and Other Demyelinating Diseases – Diagnosis and treatment of demyelinating disorders, strategies for identifying disability progression, and personalized treatment.

Neuroimmunology – Identification of pathophysiological mechanisms underlying immune-mediated disorders.

Cerebrovascular Disorders (ischemic stroke, hemorrhagic stroke, cerebral venous thrombosis, etc.) – Diagnosis and treatment of cerebrovascular diseases, early identification and management of major cardiovascular risk factors, and primary/secondary prevention of cerebrovascular disorders.

Biostatistics and Bioinformatics – Database analysis and medical statistics.

Gut Microbiota in Neurological Disorders – Investigation of the role of gut microbiota in neurological diseases, its interaction with the immune system, and potential therapeutic implications.





Research activity:

1. Research projects (maximum 3 projects)

Project director

Role of microbiota in clinical evolution of multiple sclerosis patients treated with interferon-beta: a comprehensive approach, UEFSCDI PD 80/2022, 249.600 RON, timeline 31.03.2022 – 31.04.2024

Team member

The role of the microbiome-intestine-brain axis in the progression of amyotrophic lateral sclerosis. UEFSCDI TE 74/2022, Project director: Moțățăianu Anca, sum: 450.000 RON, timeline 13.05.2022-12.05.2024.

2. Articles published in extenso (maximum 5 articles)

1. Balasa R, **Barcutean L***, Mosora O, Manu D. Reviewing the Significance of Blood-Brain Barrier Disruption in Multiple Sclerosis Pathology and Treatment. Int J Mol Sci. 2021 Aug 4;22(16):8370. 76 citations. **IF: 6.20**.
2. Balasa R, **Barcutean L***, Balasa A, Motataianu A, Roman-Filip C, Manu D. The action of TH17 cells on blood brain barrier in multiple sclerosis and experimental autoimmune encephalomyelitis. Hum Immunol. 2020 May;81(5):237-243. 61 citations. **IF: 2.85**.
3. **Barcutean L**, Farczadi L, Manescu IB, Imre S, Maier S, Balasa R. Short and Medium Chain Fatty Acids in a Cohort of Naïve Multiple Sclerosis Patients: Pre- and Post-Interferon Beta Treatment Assessment. Biologics. 2024 Nov 15;18:349-361. **IF: 5.3**.
4. **Barcutean L**, Maier S, Bajko Z, Stoian A, Mosora O, Sărmășan E, Mănescu, I.B. Bălașa R. Long-Term Disability Outcomes in Relapsing-Remitting Multiple Sclerosis Patients: Impact of Clinical and Demographic Factors on Disease Progression. J Clin Med 2024; 13(6), 1813. Citations: 1. **IF: 3**.
5. **Barcutean L**, Maier S, Burai-Patrascu M, Farczadi L, Balasa R. The Immunomodulatory Potential of Short-Chain Fatty Acids in Multiple Sclerosis. Int J Mol Sci. 2024 Mar 11;25(6):3198. Citations: 8. **FI: 4.9**.

